Design, synthesis and biological evaluation of novel 4-substituted coumarin derivatives as antitumor agents

Abstract

Herein, fifteen new compounds containing coumarin, 1,2,3-triazole and benzoyl-substituted arylamine moieties were designed, synthesized and tested in vitro for their anticancer activity. The results showed that all tested compounds had moderate antiproliferative activity against MDA-MB-231, a human breast cancer cell line, under both normoxic and hypoxic conditions. Furthermore, the 4-substituted coumarin linked with benzoyl 3,4-dimethoxyaniline through 1,2,3-triazole (compound 5e) displayed the most prominent antiproliferative activities with an IC50 value of 0.03 µM, about 5000 times stronger than 4-hydroxycoumarin (IC50 > 100 µM) and 20 times stronger than doxorubicin (IC50 = 0.60 µM). Meanwhile, almost all compounds revealed general enhancement of proliferation-inhibiting activity under hypoxia, contrasted with normoxia. A docking analysis showed that compound 5e had potential to inhibit carbonic anhydrase IX (CA IX).